Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00721344 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.
A Phase 1 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00721344 is a Phase 1 study that has completed, run by Mannkind Corporation. The registered enrollment target is 48 participants.
The verdict
NCT00721344, a Phase 1 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
48 healthy adult male \& female subjects will be enrolled in this study to determine the effect of Technosphere® Inhalation Powder (FDKP) on the QT interval of the EKG. Eligible subjects will be randomized into a dosing regimen after admission.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG Technosphere Inhalation Powder (FDKP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00721344
The ClinicalTrials.gov registry entry for NCT00721344 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00721344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00721344 about?
NCT00721344 is a clinical study titled "A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.". 48 healthy adult male \& female subjects will be enrolled in this study to determine the effect of Technosphere® Inhalation Powder (FDKP) on the QT interval of the EKG. Eligible subjects will be randomized into a dosing regimen after admission.
What is the current status of trial NCT00721344?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2008-04. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00721344?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), Technosphere Inhalation Powder (FDKP) (DRUG).
Who is sponsoring clinical trial NCT00721344?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.